C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes
Edwin K S Wong,Kevin J Marchbank,Hannah Lomax-Browne,Isabel Y Pappworth,Harriet Denton,Katie Cooke,Sophie Ward,Amy-Claire McLoughlin,Grant Richardson,Valerie Wilson,Claire L Harris,B Paul Morgan,Svetlana Hakobyan,Paul McAlinden,Daniel P Gale,Heather Maxwell,Martin Christian,Roger Malcomson,Timothy H J Goodship,Stephen D Marks,Matthew C Pickering,David Kavanagh,H Terence Cook,Sally A Johnson,MPGN/DDD/C3 Glomerulopathy Rare Disease Group and National Study of MPGN/DDD/C3 Glomerulopathy Investigators,Su Brimble,Julie Gibbs,Rodney Gilbert,Lorraine Harper,Kim Jessup,Helen Jones,Adam Levine,Andrew Longfellow,David Milford,Sandra Richardson,Stephen Richardson,Neil Sebire,Mark Taylor,Julie Wessels,Sarah Whittall,Eric Finlay,Shivaram Hegde,Caroline Jones,Moin Saleem,Manish Sinha,Nick Webb
DOI: https://doi.org/10.2215/CJN.00320121
Abstract:Background and objectives: Membranoproliferative GN and C3 glomerulopathy are rare and overlapping disorders associated with dysregulation of the alternative complement pathway. Specific etiologic data for pediatric membranoproliferative GN/C3 glomerulopathy are lacking, and outcome data are based on retrospective studies without etiologic data. Design, setting, participants, & measurements: A total of 80 prevalent pediatric patients with membranoproliferative GN/C3 glomerulopathy underwent detailed phenotyping and long-term follow-up within the National Registry of Rare Kidney Diseases (RaDaR). Risk factors for kidney survival were determined using a Cox proportional hazards model. Kidney and transplant graft survival was determined using the Kaplan-Meier method. Results: Central histology review determined 39 patients with C3 glomerulopathy, 31 with immune-complex membranoproliferative GN, and ten with immune-complex GN. Patients were aged 2-15 (median, 9; interquartile range, 7-11) years. Median complement C3 and C4 levels were 0.31 g/L and 0.14 g/L, respectively; acquired (anticomplement autoantibodies) or genetic alternative pathway abnormalities were detected in 46% and 9% of patients, respectively, across all groups, including those with immune-complex GN. Median follow-up was 5.18 (interquartile range, 2.13-8.08) years. Eleven patients (14%) progressed to kidney failure, with nine transplants performed in eight patients, two of which failed due to recurrent disease. Presence of >50% crescents on the initial biopsy specimen was the sole variable associated with kidney failure in multivariable analysis (hazard ratio, 6.2; 95% confidence interval, 1.05 to 36.6; P<0.05). Three distinct C3 glomerulopathy prognostic groups were identified according to presenting eGFR and >50% crescents on the initial biopsy specimen. Conclusions: Crescentic disease was a key risk factor associated with kidney failure in a national cohort of pediatric patients with membranoproliferative GN/C3 glomerulopathy and immune-complex GN. Presenting eGFR and crescentic disease help define prognostic groups in pediatric C3 glomerulopathy. Acquired abnormalities of the alternative pathway were commonly identified but not a risk factor for kidney failure.